RNA Modifications in Health and Disease
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 1R13AI179172-01
Grant search
Key facts
Disease
COVID-19Start & end year
2023.02024.0Known Financial Commitments (USD)
$7,500Funder
National Institutes of Health (NIH)Principal Investigator
CHIEF SCIENTIFIC OFFICER TERRY SHEPPARDResearch Location
United States of AmericaLead Research Institution
KEYSTONE SYMPOSIAResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
ABSTRACT Support is requested for a Keystone Symposia conference entitled RNA Modifications in Health and Disease, organized by Drs. Eric Miska, Ramesh S. Pillai and Eva Maria Novoa Pardo. The conference will be held in Banff, Canada from December 12-15, 2023. Chemical modifications of RNA nucleotides, collectively referred to as the epitranscriptome, represent an additional layer of information encoded in transcribed RNA sequences. By analogy to epigenetic mechanisms, RNA modifications are reversibly added by 'writer' and 'eraser' enzymes and these 'marks' are interpreted by 'reader' proteins. Characterization of the structural diversity of RNA modifications and elucidation of their roles in biological pathways represent central motivations of this emerging field, which has been supported by new technology development and mechanistic analysis by scientists interested in RNA biology. Basic discoveries in epitranscriptomics are being translated toward the clinic at an accelerating rate. Our understanding of the function and regulation of RNA modifications, as well as their roles in human infection, immunity and disease is deepening in parallel with the advancement of RNA-based medicines, such as mRNA-based COVID-19 vaccines or antisense oligonucleotides (ASOs). This conference will bring together leading experts focused on RNA modifications, technology development and medicine to discuss cutting edge research, evaluate data standards in the field and identify opportunities for the translational potential of targeting RNA modification pathways. We anticipate that participants of this conference will benefit by sharing results on this rapidly advancing topic, but also in defining the future direction of the field and creating new collaborations to accelerate progress.